In the biotech sphere, ARK ETFs continued to accumulate shares of CRISPR Therapeutics AG (NASDAQ: CRSP) and Intellia Therapeutics Inc (NASDAQ: NTLA ), with purchases of 67,787 and 194,844 shares, ...

Steward Partners Investment Advisory LLC grew its position in shares of UiPath Inc. (NYSE:PATH – Free Report) by 99.8% during ...

Stock analysts at DA Davidson upped their FY2026 earnings per share (EPS) estimates for UiPath in a research report issued on Thursday, March 13th. DA Davidson analyst G. Luria now expects that the ...

UiPath (PATH) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

ARK also bought 79,201 shares of IBOTTA INC (NASDAQ:IBTA) across its ARKW and ARKF ETFs, with a total value of approximately $3.17 million. Notably, this purchase adds to ARK’s ongoing accumulation of ...

UiPath has acquired Peak, an AI company that optimises product inventory and pricing. The acquisition strengthens UiPath's ...

Learn more about whether Manhattan Associates, Inc. or UiPath Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Open Text Corporation or UiPath Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

UiPath's growth slows to a crawl as it chases agentic AI dream with Peak acquisition, and its stock falls sharply - SiliconANGLE ...

UiPath Inc (NYSE: PATH) stock declined on weak Q4 revenue and Q1 guidance. Needham analyst reiterated Hold. Deal delays and ...

UiPath's Q4 results show margin improvements, but analyst cautions on AI transition and growth pressure, lowering price ...

UiPath has acquired Peak.ai, a startup out of Manchester that builds “decision-making” pricing and inventory management AI ...